Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 60, Issue 4, Pages 1477-1487Publisher
IOS PRESS
DOI: 10.3233/JAD-170324
Keywords
Alzheimer's disease; cerebrospinal fluid; cost-utility; economic evaluation; mild cognitive impairment; prognosis; risk
Categories
Funding
- Netherlands: ZonMW-The Netherlands Organisation for Health Research and Development [629000002]
- Sweden: Swedish Research Council [C0001401]
- Slovenia: Slovenian Research Agency
- Early Detection and rational therapy of dementia [L3-4255-0312]
- Swedish Brain Power programme
Ask authors/readers for more resources
Background: Diagnostic research criteria for Alzheimer's disease support the use of biomarkers in the cerebrospinal fluid (CSF) to improve the accuracy of the prognosis regarding progression to dementia for people with mild cognitive impairment (MCI). Objective: The aim of this study was to estimate the potential incremental cost-effectiveness ratio of adding CSF biomarker testing to the standard diagnostic workup to determine the prognosis for patients with MCI. Methods: In an early technology assessment, a mathematical simulation model was built, using available evidence on added prognostic value as well as expert opinion to estimate the incremental costs and quality-adjusted life years (QALYs) of 20,000 virtual MCI patients with (intervention strategy) and without (control strategy) relying on CSF, from a health-care sector perspective and with a 5-year time horizon. Results: Adding the CSF test improved the accuracy of prognosis by 11%. This resulted in an average QALY gain of 0.046 and (sic)432 additional costs per patient, representing an incremental cost-effectiveness ratio of (sic)9,416. Conclusion: The results show the potential of CSF biomarkers in current practice from a health-economics perspective. This result was, however, marked by a high degree of uncertainty, and empirical research is required into the impact of a prognosis on worrying, false-positive/negative prognosis, and stigmatization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available